Published on April 5, 2009 at 11:10 PM
Recent studies have questioned the wisdom of getting regular tests for prostate cancer.
Tulane University School of Medicine prostate cancer expert Dr. Oliver Sartor is available to talk about the latest treatments for prostate cancer and who should continue to seek annual tests for the deadly cancer.
Sartor is sought after by patients across the country because of his expertise in hard-to-treat cases and cutting-edge therapies at the forefront of cancer research. "Patients come to me because I deal with difficult cases, particularly those that have failed initial therapies," Sartor says. "However, I am increasingly being consulted on early-stage cases to help patients understand and balance the risks and benefits of their therapeutic options."
As a leading academic in cancer treatment, Sartor is co-author of the prostate cancer chapter in the 8th edition of Cancer: Principles & Practice of Oncology, one of today's most influential cancer texts. Sartor is also an active advocate of clinical research, and will serve as the principal investigator on a number of new prostate cancer trials set to open at Tulane, including one on abiraterone, a once-a-day pill that shows promise in shrinking tumors in men with advanced prostate cancer who had not responded to other treatments.
http://www.tulane.edu/